Activation of tyrosine kinases by mutation of the gatekeeper threonine

被引:335
作者
Azam, Mohammad [1 ,3 ]
Seeliger, Markus A. [4 ,5 ]
Gray, Nathanael S. [2 ,3 ]
Kuriyan, John [4 ,5 ]
Daley, George Q. [1 ,2 ,6 ]
机构
[1] Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA
[4] Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA
[5] Univ Calif Berkeley, Howard Hughes Med Inst, Dept Chem, Berkeley, CA 94720 USA
[6] Harvard Stem Cell Inst, Cambridge, MA 02138 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nsmb.1486
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-alpha and -beta, and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells. Structural analysis reveals that a network of hydrophobic interactions-the hydrophobic spine-characteristic of the active kinase conformation is stabilized by the gatekeeper substitution. Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase. Furthermore, a small-molecule inhibitor that maximizes complementarity with the dismantled spine (compound 14) inhibits the gatekeeper mutation of BCR-ABL-T315I. These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors.
引用
收藏
页码:1109 / 1118
页数:10
相关论文
共 57 条
[1]   A robust bulk-solvent correction and anisotropic scaling procedure [J].
Afonine, PV ;
Grosse-Kunstleve, RW ;
Adams, PD .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2005, 61 :850-855
[2]   Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].
Azam, M ;
Latek, RR ;
Daley, GQ .
CELL, 2003, 112 (06) :831-843
[3]   Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance [J].
Azam, Mohammad ;
Nardi, Valentina ;
Shakespeare, William C. ;
Metcalf, Chester A., III ;
Bohacek, Regine S. ;
Wang, Yihan ;
Sundaramoorthi, Raji ;
Sliz, Piotr ;
Veach, Darren R. ;
Bornmann, William G. ;
Clarkson, Bayard ;
Dalgarno, David C. ;
Sawyer, Tomi K. ;
Daley, George Q. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (24) :9244-9249
[4]   Anticipating clinical resistance to target-directed agents - The BCR-ABL paradigm [J].
Azam, Mohammad ;
Daley, George Q. .
MOLECULAR DIAGNOSIS & THERAPY, 2006, 10 (02) :67-76
[5]   Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR [J].
Bell, DW ;
Gore, I ;
Okimoto, RA ;
Godin-Heymann, N ;
Sordella, R ;
Mulloy, R ;
Sharma, SV ;
Brannigan, BW ;
Mohapatra, G ;
Settleman, J ;
Haber, DA .
NATURE GENETICS, 2005, 37 (12) :1315-1316
[6]  
Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
[7]   The TEL platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways [J].
Carroll, M ;
Tomasson, MH ;
Barker, GF ;
Golub, TR ;
Gilliland, DG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14845-14850
[8]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[9]   PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease [J].
Cools, J ;
Stover, EH ;
Boulton, CL ;
Gotlib, J ;
Legare, RD ;
Amaral, SM ;
Curley, DP ;
Duclos, N ;
Rowan, R ;
Kutok, JL ;
Lee, BH ;
Williams, IR ;
Coutre, SE ;
Stone, RM ;
DeAngelo, DJ ;
Marynen, P ;
Manley, PW ;
Meyer, T ;
Fabbro, D ;
Neuberg, D ;
Weisberg, E ;
Griffin, JD ;
Gilliland, DG .
CANCER CELL, 2003, 3 (05) :459-469
[10]   A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].
Cools, J ;
DeAngelo, DJ ;
Gotlib, J ;
Stover, EH ;
Legare, RD ;
Cortes, J ;
Kutok, J ;
Clark, J ;
Galinsky, I ;
Griffin, JD ;
Cross, NCP ;
Tefferi, A ;
Malone, J ;
Alam, R ;
Schrier, SL ;
Schmid, J ;
Rose, M ;
Vandenberghe, P ;
Verhoef, G ;
Boogaerts, M ;
Wlodarska, I ;
Kantarjian, H ;
Marynen, P ;
Coutre, SE ;
Stone, R ;
Gilliland, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214